Latest news
25 items- PRAzenta Announces Fiscal 2022 Fourth Quarter and Full Year Earnings Conference Call and WebcastCHELMSFORD, Mass., Nov. 7, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal fourth quarter and full year 2022 earnings which ended on September 30, 2022 on Monday, November 14, 2022 after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Monday, November 14, 2022 at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-936-4761 for domestic callers and +1-212-231-2922 for international callers. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:3
- PRAzenta Announces Completion of B Medical Systems AcquisitionCHELMSFORD, Mass., Oct. 3, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has closed its previously announced acquisition of B Medical Systems S.á r.l and its subsidiaries ("B Medical"), a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments to more than 150 countries worldwide. This acquisition complements Azenta's cold chain capabilities, adding differentiated solutions for reliable and traceable transport of temperature-sensitive specimens. B Medical, headquartered in Hosingen, Luxembourg, is one of the leading vaccine cold chain providers serving primarily fast-growing emerging markets, w
- PRAzenta to Participate in the Baird 2022 Global Healthcare ConferenceCHELMSFORD, Mass., Sept. 6, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the Baird 2022 Global Healthcare Conference in New York City, on Wednesday, September 14, 2022, which includes a presentation beginning at 9:40 am ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain
- PRAzenta to Participate in the Morgan Stanley 20th Annual Global Healthcare ConferenceCHELMSFORD, Mass., Aug. 30, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the Morgan Stanley 20th Annual Global Healthcare Conference in New York City, on Tuesday, September 13, 2022, which includes a presentation beginning at 4:40 pm ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event. About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliabl
- PRAzenta to Participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 ConferenceCHELMSFORD, Mass., Aug. 11, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 16, 2022. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. As of December
- PRAzenta Life Sciences Reports Results of Third Quarter of Fiscal 2022, Ended June 30, 2022CHELMSFORD, Mass., Aug. 9, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2022. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2022 2022 2021 Prior Qtr. Prior Yr. Revenue from Continuing Operations $ 133 $ 146 $ 129 (9) % 3 % Life Sciences Products $ 47 $ 54 $ 49 (12) % (3) % Life Sciences Services $ 85 $ 92 $ 80 (7) % 6 % Diluted EPS Continuing Operations $ (0.09) $ (0.02) $ (0.02) nm nm Diluted EPS Total $ (0.13) $ 28.28 $ 0.53 nm nm Non-GAAP Diluted EPS Continuing Operations $ 0.12 $ 0.12 $ 0.10 0 % 14 % Adjusted EBITDA Continuing Operations $ 14 $ 19 $ 19 (29) % (26) % M
- PRAzenta Announces Agreement to Acquire B Medical SystemsEnhances Azenta's Leadership Position in Cold Chain Solutions and End-to-End Sample Management CHELMSFORD, Mass., Aug. 8, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has entered into a definitive agreement to acquire B Medical Systems S.á r.l and its subsidiaries ("B Medical"), a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments across the globe. The cash purchase price to be paid at closing will be approximately €410 million. Additional cash consideration, up to €50 million, may be paid upon achievement of certain future performance milestones. The transaction is expected to close in O
- PRAzenta to Participate in the UBS Genomics 2.0 and MedTech Innovations SummitCHELMSFORD, Mass., Aug. 5, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, CA, on Thursday, August 11, 2022, which includes a presentation beginning at 4:00 pm PT. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-ch
- PRAzenta Celebrates Opening of New China HeadquartersCHELMSFORD, Mass., July 27, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced the opening of its new China headquarters in Suzhou, which serves as the hub for Azenta operations in the Asia Pacific region. The project is the largest capital investment to date for Azenta and consists of over 200,000 square feet of laboratory and office space. The new facility consolidates multiple leased spaces into a single owned facility and significantly expands the capacity of Azenta labs in China. "This strategic investment is enabling customers to advance therapeutics develop
- PRAzenta Reports Preliminary Results for Third Quarter of Fiscal 2022, Ended June 30, 2022 and Announces Earnings Conference Call and WebcastCHELMSFORD, Mass., July 13, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported preliminary results for its third fiscal quarter ended June 30, 2022. The Company expects revenue of approximately $133 million, an increase of 3% compared to the third quarter of fiscal 2021. Year-over-year organic growth is expected to be 6%, after adjusting for approximately 3 percentage points of currency impact. GAAP diluted EPS from continuing operations is expected to be in the range of ($0.13) to ($0.08), driven lower than expected primarily due to income taxes. Non-GAAP diluted EPS is expected to be in the range of $0.08 to $0.12. Revenue for the Services segment is expected to be approximatel
- PRAzenta Announces Completion of Barkey Holding GmbH AcquisitionCHELMSFORD, Mass., July 1, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has closed its previously announced acquisition of Barkey Holding GmbH and its subsidiaries ("Barkey"), a leading provider of controlled rate thawing devices for customers in the medical, biotech and pharmaceutical industries. Barkey, headquartered in Leopoldshöhe, Germany, has over four decades of expertise in the automated thawing of plasma, blood and stem cells and has an established footprint in the large and growing cell and gene therapy market serving over 100 customers to date. The acquisition extends Azenta's cold chain capabilities and enhances Azenta's reach with customers across all
- PRDaon Names Ralph Rodriguez as President & Chief Product OfficerSeasoned B2B Security Expert to Lead Company's Product Vision, Strategy, & Roadmaps Daon, a global leader in identity assurance technology, announced that Ralph Rodriguez has been named President and Chief Product Officer. Rodriguez joins the company's board of directors in this newly created role to lead the go-to-market vision, strategy, and roadmaps for Daon's products and technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220616005205/en/Ralph Rodriguez, Daon President & CPO (Photo: Business Wire) Rodriguez has a proven track record over the last 30 years in both early-stage venture-backed companies and large $1B+
- PRAzenta Announces Agreement to Acquire Barkey Holding GmbHCHELMSFORD, Mass., June 8, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has entered into a definitive agreement to acquire Barkey Holding GmbH and its subsidiaries ("Barkey"), a leading provider of controlled rate thawing devices to medical, biotech and pharma industries. Barkey is headquartered in Leopoldshöhe, Germany. Barkey has over four decades of expertise in the automated thawing of plasma, blood and stem cells and has more recently focused on cell and gene therapy (CGT) applications. Its key product lines are used for controlled rate thawing of cryopreserved samples and therapies. These products are used in R&D, clinical trials, GMP manufacturing and in hos
- PRAzenta to Participate in the Jefferies Healthcare ConferenceCHELMSFORD, Mass., June 2, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the Jefferies Healthcare Conference in New York City, on Thursday, June 9, 2022, which includes a presentation beginning at 3:30 pm ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event. About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management
- PRAzenta to Participate in the UBS Global Healthcare ConferenceCHELMSFORD, Mass., May 19, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the UBS Global Healthcare Conference in New York, on Tuesday, May 24, 2022, which includes a presentation beginning at 2:45 pm ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management sol
- PRAzenta Life Sciences Reports Preliminary Results of Second Quarter of Fiscal 2022, Ended March 31, 2022Robust customer demand bolstered by operational execution drives strong second quarter results CHELMSFORD, Mass., May 9, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported preliminary financial results for the second quarter ended March 31, 2022. Summary of Preliminary Results On February 1, 2022, the Company completed the sale of its Semiconductor Automation business. The related gain on the sale and the results of the Semiconductor Automation business are treated as discontinued operations and reflected in total diluted EPS. Due to the complexities of the financial carve-out of the business from the Company's financial results, the Company expects it will require additional
- PRAzenta Reschedules Fiscal 2022 Second Quarter Earnings Conference Call and WebcastCHELMSFORD, Mass., April 28, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has rescheduled the release of its earnings for the second fiscal quarter of 2022 which ended on March 31, 2022 from Tuesday, May 3, 2022 to Monday, May 9, 2022 after the market closes. The change is due to a delay in completing the quarter-end closing process related to the sale of the Semiconductor Automation business, which closed on February 1, 2022. Azenta currently expects second quarter revenue and non-GAAP EPS to be within the previously issued guidance range. The Company will host a conference call and live webcast to discuss its financial results on the same day, Monday, May 9, 2022
- PRAzenta Life Sciences Announces Fiscal 2022 Second Quarter Earnings Conference Call and WebcastCHELMSFORD, Mass., April 14, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal 2022 second quarter earnings which ended on March 31, 2022 on Tuesday, May 3, 2022 after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, May 3, 2022 at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-926-6194 for domestic callers and +1-212-231-2922 for international callers. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 4, 2022. Ab
- PRAzenta to Participate in the 21st Annual Needham Virtual Healthcare ConferenceCHELMSFORD, Mass., March 30, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, which includes a presentation beginning at 9:30am ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample managem
- PRAzenta to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor ForumCHELMSFORD, Mass., March 11, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 22, 2022, which includes a presentation beginning at 3:00pm ET. The conference will be held in a virtual environment. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event. About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster.
- PRAzenta to Participate in the Barclays Global Healthcare ConferenceCHELMSFORD, Mass., March 1, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the Barclays Global Healthcare Conference on Tuesday, March 15, 2022, which includes a presentation beginning at 10:15am ET. The conference will be held in Miami, FL. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reli
- PRAzenta to Participate in the Cowen 42nd Annual Health Care ConferenceCHELMSFORD, Mass., Feb. 25, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in Cowen's 42nd Annual Health Care Conference on Tuesday, March 8, 2022, which includes a presentation beginning at 2:10pm ET. The conference will be held in a virtual environment. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full su
- PRAzenta Life Sciences Reports Results of First Quarter of Fiscal 2022, Ended December 31, 2021CHELMSFORD, Mass., Feb. 8, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the fiscal quarter ended December 31, 2021. Summary of Results Results of continuing operations reflect the Life Sciences business. Due to the agreement reached in the fourth fiscal quarter of 2021 to divest the semiconductor automation business, the results of the semiconductor automation business are treated as discontinued operations and reflected in total diluted EPS. Quarter Ended Dollars in millions, except per share data December 31, September 30, December 31, Change 2021 2021 2020 Prior Qtr. Prior Yr. Revenue from Continuing Operations $ 140 $ 137 $ 118 2 % 18 % Life Sci
- PRAzenta Life Sciences to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceCHELMSFORD, Mass., Feb. 4, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 15, 2022, which includes a presentation beginning at 10:30 a.m. EST. To join the virtual event, please contact your BTIG representative. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, cli
- PRAzenta Life Sciences Completes Sale of Semiconductor Solutions Group Business to Thomas H. Lee PartnersCHELMSFORD, Mass., Feb. 1, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has completed the previously announced sale of the company's Semiconductor Solutions Group business (or "automation business") to Thomas H. Lee Partners ("THL") for $3.0 billion in cash, subject to adjustments for working capital and other items. Proceeds from the sale, net of taxes, fees and adjustments, are estimated to be approximately $2.4 billion. The company used approximately $50 million of the proceeds from the sale to extinguish the outstanding balance of its term loan facility. In conjunction, Azenta also terminated its revolving line of credit, which had no borrowings outstanding. W